Cargando…

Dupilumab, an emerging therapeutic choice for recalcitrant subepidermal autoimmune bullous diseases: a case series of three patients

Detalles Bibliográficos
Autores principales:	Liu, Xiuting, Ma, Jianchi, Qiu, Xiaonan, Hong, Dan, Wang, Liangchun, Shi, Zhenrui
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Libbey Eurotext 2022
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8853335/ https://www.ncbi.nlm.nih.gov/pubmed/35107075 http://dx.doi.org/10.1684/ejd.2021.4190

Ejemplares similares

Recalcitrant bullous pemphigoid responsive to dupilumab in an adolescent patient
por: Zhou, Albert E., et al.
Publicado: (2022)

Case Report: Combination of Omalizumab and Dupilumab for Recalcitrant Bullous Pemphigoid
por: Seyed Jafari, S. Morteza, et al.
Publicado: (2021)

Effectiveness and safety of Dupilumab for the treatment at 104 weeks of recalcitrant bullous pemphigoid
por: Manzo Margiotta, Flavia, et al.
Publicado: (2023)

Tissue Factor in Dermatitis Herpetiformis and Bullous Pemphigoid: Link between Immune and Coagulation System in Subepidermal Autoimmune Bullous Diseases
por: Zebrowska, Agnieszka, et al.
Publicado: (2015)

Detection of Anti-basement Membrane Zone Antibodies in the Blister Fluid in Subepidermal Autoimmune Bullous Diseases
por: Surya, Ravindran, et al.
Publicado: (2017)

Accessible Diagnostic Methods to Differentiate between Epidermolysis Bullosa Acquisita and Other Subepidermal Autoimmune Bullous Diseases
por: Kridin, Khalaf
Publicado: (2018)

Histologic characterization of cellular infiltration in autoimmune subepidermal bullous diseases in a tertiary hospital in Saudi Arabia
por: BinJadeed, Hessah F, et al.
Publicado: (2018)

SALT SPLIT TECHNIQUE: A USEFUL TOOL IN THE DIAGNOSIS OF SUBEPIDERMAL BULLOUS DISORDERS
por: De, Abhishek, et al.
Publicado: (2010)

Subepidermal blistering eruptions, including bullous pemphigoid, following COVID-19 vaccination
por: Tomayko, Mary M., et al.
Publicado: (2021)

Profiling Serum Cytokines and Anticytokine Antibodies in Psoriasis Patients
por: Hong, Dan, et al.
Publicado: (2022)

Spontaneous autoimmune subepidermal blistering diseases in animals: a comprehensive review
por: Bizikova, Petra, et al.
Publicado: (2023)

Recalcitrant anal and genital pruritus treated with dupilumab()()()()
por: Yang, E.J., et al.
Publicado: (2018)

Recalcitrant prurigo nodularis treated successfully with dupilumab
por: Rambhia, Pooja H., et al.
Publicado: (2019)

The use of dupilumab for the treatment of recalcitrant brachioradial pruritus
por: Abel, Mary Kathryn, et al.
Publicado: (2021)

Dupilumab monotherapy suppresses recalcitrant pemphigus vulgaris
por: Moore, Angela Y., et al.
Publicado: (2022)

Recalcitrant Palmar-Plantar Atopic Dermatitis Successfully Treated with Dupilumab: A Case Series
por: Deng, Lin, et al.
Publicado: (2022)

The Effectiveness and Safety of Dupilumab for the Treatment of Recalcitrant Chronic Actinic Dermatitis: A Case Series
por: Chen, Jiaoquan, et al.
Publicado: (2023)

ULK1 Inhibition as a Targeted Therapeutic Strategy for Psoriasis by Regulating Keratinocytes and Their Crosstalk With Neutrophils
por: Qiu, Xiaonan, et al.
Publicado: (2021)

Recalcitrant generalized granuloma annulare treated successfully with dupilumab
por: Song, Eingun James, et al.
Publicado: (2020)

Co-existence of Rheumatoid Arthritis, Vitiligo, and Bullous Pemphigoid as Multiple Autoimmune Syndrome
por: Sundaram, Murugan, et al.
Publicado: (2014)

Efficacy and Safety of Dupilumab in Moderate-to-Severe Bullous Pemphigoid
por: Zhang, Yihua, et al.
Publicado: (2021)

Use of Dupilumab in Bullous Pemphigoid: Where Are We Now?
por: Russo, Roberto, et al.
Publicado: (2022)

Effect of Dupilumab on Generalized Verrucosis in Refractory Bullous Pemphigoid
por: WANG, Qijun, et al.
Publicado: (2023)

Recalcitrant infantile bullous pemphigoid successfully treated with cyclosporine
por: Bar-Ilan, Efrat, et al.
Publicado: (2022)

The microbiome extends to subepidermal compartments of normal skin
por: Nakatsuji, Teruaki, et al.
Publicado: (2013)

USE OF METHOTREXATE IN RECALCITRANT ECZEMA
por: Mittal, Asit, et al.
Publicado: (2011)

Commentary: Efficacy and Safety of Dupilumab in Moderate-to-Severe Bullous Pemphigoid
por: Wang, Si-Hang, et al.
Publicado: (2021)

The Successful Treatment of COVID-19-Induced Bullous Pemphigoid With Dupilumab
por: Savoldy, Michelle A, et al.
Publicado: (2022)

Cutaneous Cytomegalovirus Infection Presenting As Recalcitrant Bullous Pemphigoid Lesion
por: Baek, Gayun, et al.
Publicado: (2023)

Cutaneous Dermatophytosis Mimicking Bullous Pemphigoid or Typical Bullous Pemphigoid and Tinea Incognito?
por: Andrés, Tirado-Sánchez, et al.
Publicado: (2019)

Bullous prurigo pigmentosa following a ketogenic diet
por: Mao, Dan-Dan, et al.
Publicado: (2021)

LOCALIZED FLEXURAL BULLOUS PEMPHIGOID
por: Mehta, Vandana, et al.
Publicado: (2008)

Recalcitrant erythrodermic ichthyosis with atopic dermatitis successfully treated with Dupilumab in combination with Guselkumab
por: Steinhoff, M., et al.
Publicado: (2021)

Recalcitrant Hailey-Hailey disease successfully treated with topical ruxolitinib cream and dupilumab
por: Khang, Juna, et al.
Publicado: (2023)

Dupilumab for the treatment of pembrolizumab‐induced bullous pemphigoid: A case report
por: Pop, Samantha R., et al.
Publicado: (2022)

Autoimmune bullous disease in skin of color: A case series
por: Tamazian, Shant, et al.
Publicado: (2020)

Subepidermal Calcified Nodule in a Child With Neurofibromatosis Type 1
por: Bagci, Buket, et al.
Publicado: (2022)

Letter in response to the case report: “Recalcitrant generalized granuloma annulare treated successfully with dupilumab”
por: Paganini, Claudia, et al.
Publicado: (2023)

Rituximab, Omalizumab, and Dupilumab Treatment Outcomes in Bullous Pemphigoid: A Systematic Review
por: Cao, Peng, et al.
Publicado: (2022)

Case report: Successful treatment of non-bullous lichen planus pemphigoides with dupilumab
por: Li, Si-Zhe, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_k9sv9mbrl4ph4vgtgi0ik38m7r